LabCorp's Drug Development Business, Covance, Acquires GlobalCare
LabCorp recently announced the company’s drug development business, Covance, has acquired GlobalCare, a globally recognized industry leader in patient-centric decentralized clinical trials support services.
This acquisition will expand Covance’s decentralized clinical trials capabilities globally, enabling recruitment and increasing access to trials. It will also benefit GlobalCare’s current and future customers by providing access to needed resources and technology to scale services to meet growing industry needs.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025